Running Title: YB-1 controls human breast cancer initiation and metastasis 
INTRODUCTION
Mammalian Y-box binding protein-1 (YB-1) is a member of the family of DNA/RNA binding proteins with an evolutionarily conserved cold-shock domain (CSD). Mammalian CSD proteins are widely expressed and involved in many fundamental processes including DNA repair as well as mRNA transcription, splicing, translation, and stabilization (1, 2) . Elevated YB-1 expression correlates with poor patient survival and drug resistance in diverse tumor types, notably in metastatic tumors (3, 4) . In high-risk sarcomas, YB-1 drives metastasis by inducing a hypoxiainducible factor 1α (HIF1α) response (5), via its ability to bind directly to HIF1A mRNA and thereby activate YB-1 translation under hypoxia. YB-1 also induces stress granule formation through translational activation of G3BP1 mRNAs present in sarcomas and other tumor types (6). YB-1 also binds to SNAIL1 and TWIST mRNAs to activate their translation in immortalized but nontumorigenic MCF10A human mammary cells overexpressing HRAS (7). This suggests how transformed breast cells would be stimulated to undergo an epithelial-to-mesenchymal transition (EMT), a consequent disruption of their ability to sustain an acinar architecture, and increased invasive and metastatic properties. However, a lack of de novo models of breast cancer development from freshly isolated normal human mammary cells has made it difficult to determine if and how YB-1 deregulation may contribute to the initial stages of human mammary cell transformation.
We recently developed an efficient and reproducible method for rapidly generating serially transplantable invasive ductal carcinomas (IDC) by lentiviral transduction of freshly isolated normal human mammary cells with a KRAS G12D cDNA (8). This approach can be used to transforms two types of mammary cells with innate epidermal growth factor (EGF)-dependent proliferative potential, both of which can be readily isolated from normal human breast tissue.
These two cell types are referred to as basal cells (BCs) and luminal progenitors (LPs), the latter representing a phenotypically and biologically distinct subset of the luminal cell compartment (9). Although KRAS mutations are limited to approximately 4% of all human breast cancers (10), altered KRAS expression has a high oncogenic score for both estrogen receptor-positive (ER   +   ) and ER − tumors (11). The tumors produced when either normal BCs or LPs forced to express KRAS G12D are transplanted into immunodeficient mice are highly polyclonal and phenotypically heterogeneous, with a variable content of cells positive for ER, heregulin-2 (HER2), EGFR,
Ki67 and cytokeratins (CK) 8/18 (8).
We now show that increased expression of YB-1 constitutes an early and pervasive requirement for human mammary cells with deregulated KRAS activity. This is required for these cells not only to initiate but also to sustain more aggressive malignant properties, even when other mutations have been acquired a priori. In addition, we present evidence that mutant KRAS induction of YB-1 expression is associated with the activation of a HIF1α program.
RESULTS

YB-1 protein expression is increased in human breast cancers with mutant KRAS
To investigate the initial effect of KRAS G12D -induced transformation of human mammary cells on YB-1 expression, we first examined our previously published RNA-seq data for 3 paired isolates of BCs and LPs obtained by fluorescence-activated cell sorting (FACS) and matching primary tumors derived from each isolate (8). These comparisons showed a consistent decrease in YB-1 transcript levels in the transformants as compared to the normal cells from which the tumors had been generated (Fig. 1A) . However, immunohistochemical (IHC) staining of sections of primary tumors produced from either BCs or LPs with anti-YB-1 antibodies showed consistent strong YB-1 protein expression in most of the tumor cells, mainly in the cytoplasm, although occasional tumor cells also showed evidence of nuclear YB-1 (Fig. 1B) . In contrast, similarly stained sections of normal human breast tissue showed YB-1 to be largely restricted to cells in the luminal layer of the gland, primarily at low levels in the cytoplasm ( Figure 1B , left panel).
Western blot (WB) analyses of FACS-purified isolates of BCs and LPs, and also of the remaining luminal cells (LCs) of normal human mammary glands confirmed that YB-1 protein levels are highest in normal LPs and barely detectable in BCs or LCs (Fig. 1C) .
To determine if upregulated YB-1 protein expression is associated specifically with an oncogenic form of KRAS in patients' breast cancers, we first examined the publicly available data for approximately 800 breast cancers in The Cancer Genome Atlas (TCGA) (12). This revealed YBX1 transcripts to be highest in ER -tumors, and most notably in those that had metastasized (Supplementary Fig. S1A and S1B). Interestingly, in this dataset, elevated YBX1 transcripts were positively associated with a gain of function or amplification of the KRAS gene, for which reduced overall survival was observed (Fig. 1D) , as compared to patients whose tumors contained a normal diploid KRAS complement (Fig. 1E , left panel). Increased YBX1 mRNA levels were also seen in tumors with amplified ERB2, PIK3CA or AKT1, or deletions of TP53, compared to diploid breast cancers (Fig. 1E , right panel and Supplementary Fig. S1C ).
However, elevated YBX1 expression was not an evident feature of breast cancers containing HRAS or NRAS mutations (data not shown). Examination of the larger METABRIC dataset for 2,433 breast cancers (11) confirmed that increased YBX1 transcripts are associated with KRAS amplification (Fig. 1F) . In another large study of metastatic breast cancers (13) , YBX1 expression correlated with that of KRAS, but showed no association with alterations of ERBB2, TP53, PIK3CA or AKT1 (Fig. 1G ). (Fig. 3B) . In sharp contrast, markedly increased expression of YB-1 was seen in the nascent de novo tumors recovered 2 weeks after transplanting the cells into mice (Fig. 3C) , as compared to normal breast mammoplasty reduction tissue (Fig. 1B) . Indeed, at 2 weeks post-transplantation the rapidly increased level of YB-1 protein in the KRAS G12D -transduced cells was already equivalent to that seen in the invasive tumors analyzed 4-6 weeks later ( Fig. 1B and Fig. 3C (Fig. 4A) .
YB-1 is required for tumor initiation by
Inclusion in this screen of a vector encoding YB-1 showed that forced expression of YB-1 alone was insufficient to induce tumor formation as indicated by a lack of increasing bioluminescence in vivo, and also did not further enhance tumor growth when the cells were cotransduced with KRAS G12D (Fig. 4A ). Neither dominant-negative forms of TP53 nor mutant PI3K
were able to induce tumorigenesis on their own, as found previously (8) 
YB-1 expression is elevated in tumors produced from an established tumorigenic breast cancer cell line and is required for its metastatic ability
We next designed experiments to determine whether YB-1 expression might also play a critical 
KRAS activation leads to an increased HIF1α response through YB-1
To decipher how KRAS G12D and YB-1 cooperate to promote tumor progression, we performed
RNAseq and proteomic analyses of tumors generated from MDA-MB-231 cells stably expressing shYB-1 or a shScr-construct ( Fig. 6A and Supplementary Fig. S4A-B) . From these analyses, we identified several candidate target genes whose encoded RNAs and proteins increased or decreased in concert with YB-1 inhibition ( Supplementary Fig. S4A-B ). This revealed many proteins encoded by genes whose expression was similarly altered. Several of these (e.g., PPIF, SLC3A2 and SLC7A1) are related to hypoxia (16) (17) (18) and also found to be increased in patients' breast cancers with gain of function mutations or amplification of KRAS as compared to tumors with diploid KRAS (Fig. 6C and Supplementary Fig. S4B ), as well as in others with increased expression or amplified YBX1 ( Fig. 6D and Supplementary Fig. S4C ).
Notably, expression of PPIF, SLC3A2 and SLC7A1 was not further modulated in stably shYB-1-transduced MDA-MB-231 cells maintained in 2D cultures ( Figure S4A -B), and these cells also showed no alterations in cell cycle progression (Fig. 5D ).
These findings suggested a link between YB-1 expression and an altered hypoxia response in breast tumors harboring oncogenic KRAS mutations or deregulated KRAS signaling.
Previously, YB-1 was found to be a primary regulator of HIF1α protein expression in sarcoma cells (5). We therefore asked whether HIF1α expression and that of its direct transcriptional target, CAIX (carbonic anhydrase 9) (19) , were also altered in tumors produced in mice transplanted with stably shScr-versus shYB-1-transduced normal mammary ( Fig. 6E-F Fig. S5D ). Finally, patient s' breast cancers with amplified KRAS show a strong correlation between YBX1 and CAIX mRNA levels (Fig. 6H) . Together, these data point to an activated YB-1/HIF1α-mediated hypoxia response pathway in KRAS G12D driven breast cancers (Fig. 1D ).
DISCUSSION
In this study, we show that elevated expression of YB-1 plays a requisite role in enabling 
METHODS
Cells and cultures
Normal human reduction mammoplasty discard tissue was collected with informed consent, Following FACS, cells were transduced or cultured in SF7 media supplemented with 5% FBS.
MCF10A cells (obtained from J Brugge, Harvard University, Cambridge, MA) were maintained in phenol-free DMEM/F12 nutrient mix supplemented with 5% horse serum, 10 mg/ml insulin, 0.5 mg/ml hydrocortisone, 100 ng/ml cholera toxin, 20 ng/ml EGF (all Sigma), and 1% penicillin/streptomycin (Life Technologies). 3D assays of human mammary cells were performed by culturing the cells in the presence of irradiated 3T3 fibroblasts for 8, 10 or 14 days in Matrigel (Corning) SF7 media supplemented with 5% FBS as previously described (22) .
MDA-MB-231 cells were obtained from S. Dunn (Child and Family Research Institute,
Vancouver, BC) and maintained in DMEM with 10% FBS. Their identity was confirmed by DNA sequencing, including detection of the KRAS G13D allele (15).
Transduction and transfection
Primary cells were transduced with lentiviral vectors prepared and used as previously described (8). For transient inhibition of YB-1, primary human mammary cells were transfected with siYB-1 (siRNA1, 5′-UGACACCAAGGAAGAUGUA-3′; siRNA 2, 5′-GUGAGAGUGGGGAAAAGAA-3′, from GE Healthcare), using RNAiMAX following the manufacturer's protocol (Thermofisher). For stable inhibition, shYB-1 (sc-38634-V, Santa Cruz) or shScr (sc-108080) lentiviral particles were used.
Xenografts
NRG mice were bred and housed in the animal facility at the British Columbia Cancer Research
Centre. Surgery was performed on 5-to 10-week-old mice. All experimental procedures were approved by the University of British Columbia Animal Care Committee.
To generate primary tumors, enzymatically dissociated human mammary cell suspensions were prepared, transduced and transplanted subcutaneously with 50% (v/v) Matrigel into mice (8). To measure tumor bioluminescence from expressed luciferase, mice were injected intraperitoneally with 150 mg/kg body weight of d-luciferin (Promega) and 10 minutes later the mice were imaged using a Xenogen IVIS Lumina system with Living Image version 3.0 software (Caliper Life Sciences). To prepare cell suspensions from tumors, the tissue was minced with a scalpel, incubated at 37 °C in DMEM/F12 media supplemented with 5% FBS and 300 U/ml collagenase and 100 U/ml hyaluronidase for 1 to 2 hours with periodic vortexing, washed with HF, and treated with 2.5 mg/ml trypsin with 1 mM EDTA and 5 mg/ml dispase with 100 μg/ml
DNaseI. Human cells were sorted after staining with anti-human specific antibodies directed against EpCAM and CD298 (Biolegend) with simultaneous depletion of mouse cells stained with anti-mouse-specific antibodies directed against CD45 and CD31 (Biolegend).
Immunohistochemical (IHC) staining
Pieces of tumors obtained from mice or normal breast were fixed in 10% buffered formalin Student's t-test was used for data analysis, unless indicated otherwise.
Plasmids
Inducible KRAS G12D -encoding vector was derived from pINDUCER21 backbone (23) by replacing the attR1-ORF-attR2 cassette with a Kras-2A-KO2 fragment.
Western blot and densitometry analysis
After the required treatment, cells were washed with cold PBS and incubated for 15 minutes at 4°C with RIPA lysis buffer (30 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100 (Sigma) supplemented with a 1 mM NaF, 1 mM NaVO3 and 1 mM PMSF (all Sigma).
Cells extracts were centrifuged at 13,000 g for 10 minutes at 4°C. The protein concentration of the supernatant fraction was determined using the Bio-Rad Bradford Protein Assay Kit according to the manufacturer's instructions. For each sample, an equal amount of total protein was diluted in sample buffer (Invitrogen) and boiled for 5 minutes. Samples were loaded onto precast 
Proteomic data
Tissues were thawed and lysed in 100 μL lysis buffer containing 500 mM Tris-HCL pH 8, 2%
SDS (w/v), 1% NP-40 (v/v), 1% Triton X100 (v/v), 0.5 mM EDTA, 50 mM NaCl, 10 mM Tri(2-carboxyethyl)phosphine (TCEP) and 40 mM chloroacetamide (CAA). The proteins were then denatured by heating at 95°C for 90 minutes with shaking at 1100 rpm before incubation at room temperature for 90 minutes in the dark to allow reduction and alkylation of disulfide bonds by TCEP and CAA respectively. SP3 beads (28,29) were added and the tissues were sonicated in a Bioruptor Pico (Diagenode) for 10 cycles (30 seconds ON, 30 seconds OFF). The samples were purified and prepared for trypsin digestion using the SP3 method (29). Tryptic peptides from each sample were individually labeled with TMT 10-plex labels (Thermo Scientific), pooled, and fractionated into 12 fractions by high pH RP-HPLC, desalted, and then analyzed using an EasynLC1000 liquid chromatograph (LC) (Thermo Scientific) coupled to a Orbitrap Fusion Tribrid mass spectrometry (MS) (Thermo Scientific) operating in MS3 mode. The offline peptide fractionation and LC-MS conditions are as described (29). The raw MS data were searched using Proteome Discoverer (version 2.1.1.21) using the embedded Sequest HT algorithm against a combined UniProt Human proteome database with a list of common contaminants appended (24,624 total sequences). Sequest HT parameters were specified as: trypsin enzyme, allowance for 2 missed cleavages, minimum peptide length of 6, precursor mass tolerance of 20 ppm, and a fragment mass tolerance of 0.6. Dynamic modifications allowed were oxidation of methionine residues, and TMT at lysine residues and peptide N-termini. Carbamidomethylation of cysteine residues was set as a static modification. Peptide spectral match (PSM) error rates were determined using the target-decoy strategy coupled to Percolator modeling of positive and false matches (30,31). Data were filtered at the PSM-level to control for false discoveries using a qvalue cutoff of 0.05 as determined by Percolator. Contaminant and decoy proteins were removed from all datasets prior to downstream analysis. Statistical analysis of differential protein expression was performed at the peptide level using a modified version of the PECA function that is appropriate for input of log-transformed data (32). PECA uses Limma (33) to generate a linear model for estimating fold changes and standard errors prior to empirical Bayes smoothing.
Median t-statistics of the assigned peptides were used to calculate false-discovery rate-adjusted p-values determined from the beta distribution, as described previously (32).
RT-PCR
Total RNA was extracted from cryopreserved tumor samples or cultured cells using the Total RNA Isolation Micro kit (Agilent) and cDNA then synthesized using SuperScript VILO cDNA synthesis kit (Life Technologies). RT-PCR was performed using a SYBR Green master mix (Applied Biosystems) and samples run in triplicate with custom-designed primers.
Statistical analyses
Values are expressed as mean ± SEM, unless otherwise specified. Significance was evaluated using Student's t-test, unless otherwise specified. *P<0.05, **P<0.01, ns = not significant. 
